Abstracts tagged "SLE and belimumab"

Abstract Number: 1086 • 2016 ACR/ARHP Annual Meeting
Analysis of the Naive B Cell Repertoire in Belimumab Treated SLE Patients
Weiqing Huang¹, Cynthia Aranow², Cosmin Dascalu¹, Richard Furie³ and Anne Davidson⁴, ¹Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ²The Feinstein Institute for Medical Research, Manhasset, NY, ³Division of Rheumatology, North Shore LIJ Health System, Great Neck, NY, ⁴Autoimmunity and Musculoskeletal Diseases, Feinstein Inst for Med Rsch, Manhasset, NY
Background/Purpose: BAFF is a TNF-like cytokine that supports the survival and differentiation of B cells. The anti-BAFF antibody belimumab is the only new drug that…
Abstract Number: 1603 • 2013 ACR/ARHP Annual Meeting
Sustained Reductions In Circulating B Cell Populations and Immunoglobulin G Levels With Long-Term Belimumab Treatment In Patients With Systemic Lupus Erythematosus
Herbert Struemper¹, William Freimuth², Christi Kleoudis³, Thi-Sau Migone⁴, David Roth³ and William Stohl⁵, ¹GlaxoSmithKline, Research Triangle Park, NC, ²Human Genome Sciences, Inc., Rockville, MD, ³GlaxoSmithKline, King of Prussia, PA, ⁴Igenica, Burlingame, CA, ⁵Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Belimumab treatment in autoantibody-positive systemic lupus erythematosus (SLE) patients for up to 76 weeks results in sustained reduction in several circulating B cell subsets,…
Abstract Number: 1574 • 2013 ACR/ARHP Annual Meeting
Favorable Clinical Response To Belimumab At Three Months
Anca Askanase¹, Arthi Reddy¹, Jill P. Buyon², Andrew G. Franks Jr.³, Richard A. Furie⁴, Diane L. Kamen⁵, Susan Manzi⁶, Michelle Petri⁷, Rosalind Ramsey-Goldman⁸, Chung-E Tseng⁹, Ronald F. van Vollenhoven¹⁰ and Daniel J. Wallace¹¹, ¹Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ³Dermatology & Medicine (Rheumatology), New York University, New York, NY, ⁴The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹NYU School of Medicine, New York, NY, ¹⁰Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Belimumab (Benlysta) is a human monoclonal antibody that inhibits soluble B-Lymphocyte Stimulator and improves SLE disease activity. This study was initiated to evaluate the…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.